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Lysophosphatidylcholine is a bioactive lipid that regulates a large number of cellular processes and is especially present during
the deposition and inﬁltration of inﬂammatory cells and deposition of atheromatous plaque. Such molecule is also present in
saliva and feces of the hematophagous organism Rhodnius prolixus, a triatominae bug vector of Chagas disease. We have recently
demonstrated that LPC is a modulator of Trypanosoma cruzi transmission. It acts as a powerful chemoattractant for inﬂammatory
cells at the site of the insect bite, which will provide a concentrated population of cells available for parasite infection. Also, LPC
increases macrophage intracellular calcium concentrations that ultimately enhance parasite invasion. Finally, LPC inhibits NO
production by macrophages stimulated by live T. cruzi, and thus interferes with the immune system of the vertebrate host. In the
present paper, we discuss the main signaling mechanisms that are likely used by such molecule and their eventual use as targets to
block parasite transmission and the pathogenesis of Chagas disease.
1. ImmuneResponse to Trypanosoma cruzi
I nf ectio ninth eV e rt eb rat eH ost
T. cruzi infects the vertebrate host through bite wounds
produced in skin by a feeding bug or through the interaction
of the parasite with conjunctival mucosa. Such interaction
sometimes produces visible signs called Roma˜ na’s sign or
chagoma inoculation. The histology of this initial site of in-
f e c t i o ni sd e ﬁ n e db ya ne l e v a t e dn u m b e ro fm o n o n u c l e a r
cells [1]. This ﬁrst sign of infection suggests that T. cruzi can
stimulate skin cells to produce mediators that trigger a local
inﬂammatory response. Despite controversies about the
mechanism of the pathogenesis of Chagas disease [2–5],
until recently, some authors believed that the disease was
limited to an acute phase, followed by a chronic phase that
was considered an autoimmune disease, where the parasites
would be physically linked to sites of inﬂammation in the
heart and esophagus [6–8]. However, nowadays, the disease
is considered multifactorial, with multiple and continu-
ous interactions between pathogen and host [9]. After the
incubation period of 2 to 3 weeks, infection with T. cruzi is
manifested by the presence of a large number of parasites in
the blood and tissues. Acute infection is accompanied by an
excessive activation of the immune system that includes the
production of high levels of cytokines, intense activation of
T and B cells, lymphadenopathy, splenomegaly, and intense
inﬂammation associated with tissue infection niches. The
acute phase induces the development of an eﬀective acquired
immunity leading to the control of parasitemia. The chronic
phase is considered lifelong and is associated with only a few
parasitesinthehost.Thebeginning ofchronicinfectionwith
T. cruzi is asymptomatic in most patients. However, with
the advance of the disease, clinical manifestations become
variable, ranging from no symptoms to the involvement of
cardiovascular and/or gastrointestinal symptoms [10, 11].
Before the acquired immunity is established, the innate
immune system appears to be essential for at least two
important aspects of Chagas disease: control of replication of
the parasite in the host tissue and progress of the inﬂamma-
tory reaction. The latter, in turn, has been considered to be2 Journal of Parasitology Research
the main cause of tissue damage and dysfunction of certain
organsinthehost[11].Somestudiesinexperimentalmodels
of infection of T. cruzi suggest that the potent immune
response to Th-1 CD4 and CD8 cells, with the production of
speciﬁc inﬂammatory cytokines, such as interferon gamma
(IFN-γ), tumour necrosis factor (TNF-α), and interleukin
12 (IL-12), as well as the production of reactive nitrogen
species such as nitric oxide (NO), plays an important role
in the control of parasitemia during the initial stage of the
disease [4, 10–13]. Moreover, cells of innate immunity, such
as natural killer (NK) cells, dendritic cells, and macrophages,
are also key elements in the initial control of parasite
replication [10–13].
In recent years, research on Chagas disease has focused
on the investigation of the role of pathogen-associated
molecular patterns (PAMPs) of protozoa, which are the tar-
gets of innate immune receptors. Also, the problem of iden-
tifying relevant receptors in innate immunity-parasite inter-
actions during the evolution of the disease in the host
has been addressed by several laboratories. This strategy
ultimately aims at the development of therapeutic inter-
ventions through the use of PAMPs derived from parasites.
Glycosyl-phosphatidyl-inositol (GPI) is the name given to
the ﬁrst glycoconjugate in T. brucei that was identiﬁed with
the function of anchoring proteins on the cell surface [14–
17]. PAMPs widely studied in T. cruzi are, in fact, GPI
anchors. All evolutive forms of this parasite express on their
surface GPI-anchored glycoproteins [14–17]. Some studies
have identiﬁed GPI anchors isolated from trypomastigote-
derived mucin-like glycoproteins (GPI-mucins) of T. cruzi
as the molecules primarily responsible for stimulating the
host immune system [18, 19]. Thus, T. cruzi GPI-mucins are
able to activate macrophages and stimulate the production
of proinﬂammatory cytokines, chemokines, and NO [20–
22]. Innate immune response to T. cruzi has been studied
extensively and is based on the activation of signaling
pathways triggered by Toll-like receptors (TLRs). TLRs
are proteins that recognize conserved motifs associated
with several diﬀerent pathogens; they trigger intracellular
signaling cascades that ultimately lead to a complex host
immune response [11, 12] .T h e r ea r e1 0T L R sd e s c r i b e di n
h u m a n sa n d1 2i nm i c e[ 11, 12]. Generally, the stimulus
induced by GPI molecules occurs during the early phase of
infection, where macrophages respond to trypomastigotes
in a TLR-dependent mechanism and ultimately induce the
production of IL-12 and TNF-α and trigger the responses of
CD4 and CD8 cells through the production of IFN-γ [23].
Thus, macrophages activated by TNF-α and IFN-γ seem to
have an important role in controlling parasite growth. Free
GPI anchors or glycoinositolphospholipids (GIPLs) are also
able to stimulate the host immune system. GIPLs are similar
to GPIs but contain instead ceramide in their lipid moiety
[18, 19].
TLRs 2, 4, and 9 are the major TLRs involved in innate
immune response to T. cruzi [18, 24–29]. TLR2 has been
identiﬁed as the main receptor responsible for macrophage
activation by GPI mucins [18, 24–29]. According to Ropert
and Gazzinelli [27], the receptor heterodimer composed of
TLR2 and TRL6 is activated by GPI mucin and the CD14
coreceptor. Oliveira et al. [25] observed that GIPL from T.
cruziconfersaninﬂammatoryresponseviaTLR4,promoting
the recruitment of neutrophils into the peritoneal cavity
of mice. Later, Medeiros et al. [26] demonstrated that this
eﬀect was partially dependent on the production of IL-1β.
The genomic DNA of T. cruzi also plays an important role
in proinﬂammatory response of the vertebrate host during
infection, since TLR 9 is activated by CpG motifs from
nonmethylated DNA [28, 29]. Besides the innate immune
response mediated by TLRs, T. cruzi can also stimulate TLR-
independent pathways that lead to the production of IFN-
β and IFN-γ. In this case, this occurs due to a surge in
intracellular calcium concentration which ultimately leads to
the activation of calcineurin and calmodulin [30–32].
2. Lysophosphatidylcholine and Modulation of
NO ProductionandHost Immunity
Lysophospholipids such as lysophosphatidylcholine (LPC),
sphyngosylphosphoryilcholine (SPC), lysophosphatidic acid
(LPA), and sphingosine-1-phosphate (S1P) regulate a large
number of cellular processes. LPC is a derivative of phos-
phatidylcholine (PC) that arises by the loss of a fatty acid
through the action of a phospholipase A2 (PLA2)o rb y
transferring it to cholesterol by the action of a cholesterol-
acetyltransferase [33]. LPC is involved in several physio-
logical events and is already known as a central molecule
in several pathological states, but it is especially present
during the deposition and inﬁltration of inﬂammatory cells
and deposition of atheromatous plaque [34–36]. Research
directed towards LPC has increased greatly since the ﬁnding
that these molecules are involved in atherosclerosis [37].
The idea that various phospholipases secreted by circu-
lating leukocytes participate in this pathology was soon
proposed.Thus,thecurrentmodelsuggeststhatdiabetesand
hypercholesterolemia contribute to generate a large number
of LDL particles in plasma that can undergo oxidation
of unsaturated fatty acids, generating an oxidized particle
(oxLDL). Since on average 50% of LDL fatty acids are
arachidonic acid and linoleic acid, the chances of such an
oxidative event are huge. The oxLDL is a potential cause of
the increased expression of inﬂammatory markers such as
TNF-α, MCP-1, and MCSF that will attract diﬀerentiating
monocytes to the lesion site. In this sense, LPC is one of the
most powerful chemotactic signals for macrophages and is
also generated by cells in the apoptotic process as mentioned
above. OxLDL particles are recognized by various secretory
PLA2 in the plasma, including type IIA, V, and X. Our group
showed for the ﬁrst time the presence of phospholipids and
lysophospholipids in saliva and feces of the hematophagous
organism Rhodnius prolixus, a triatominae bug vector of
Chagas disease [38]. The major lipids present in R. prolixus
saliva are PC and LPC [38]. Salivary LPC is an additional
antihemostatic molecule that is part of the pharmacological
arsenal injected into the bite site to allow the insect to feed. It
inhibits platelet aggregation and increases the production of
NO in endothelial cells. Thus, LPC was initially described as
a molecule with antiplatelet and vasodilatory activities, andJournal of Parasitology Research 3
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Figure 1: LPC-induced signaling on monocytes and macrophages. LPC is a signaling molecule that may act through diﬀerent receptors on
cell surface such as G2A and GPC4. Despite its description as a proinﬂammatory molecule, LPC-mediated signaling through TLRs is not
demonstrated yet. LPC induces cell chemotaxis which ultimately increases the number of cells in the wound site. Also, LPC-treated cells
undergo a decrease on NO synthesis when stimulated by parasite or LPS. Finally, a transient increase on intracellular calcium is also reported
in such cells. These combined eﬀects enhance the number of cells prone to T. cruzi invasion.
a few years later, its eﬀect as an immunomodulator of T.cruzi
infection was demonstrated [38, 39].
The role of LPC as a modulator of T. cruzi transmission
occurs by three main mechanisms summarized on Figure 1
and mentioned as follows.
(1)LPCisav ect or -deri v edmolecule.I tactsasapo w erful
chemoattractant for inﬂammatory cells at the site of the
insectbite.Thiseventwillprovideaconcentratedpopulation
of cells available for T. cruzi infection [38, 39].
(2) LPC increases macrophage intracellular calcium
concentrations that ultimately enhance parasite invasion.
(3) LPC inhibits NO production by macrophages stim-
ulated by either live T. cruzi,L P S ,o rL P Si nt h ep r e s e n c eo f
IFN-γ, and thus interferes with the immune system of the
vertebrate host [39].
The above ﬁndings demonstrate that LPC is now a
signaling molecule with eﬀects beyond that of counteracting
host blood hemostasis, since it acts as modulator of NO
biology and parasite transmission [40–43]. Macrophages are
intimately related to the establishment of acute infection
with T. cruzi, since the success of the infection depends
on the initial invasion of these cells [44–46]. This leads to
the assumption that salivary LPC may facilitate the parasite
infection,favoringnotonlyinsectfeeding,butalsopreparing
the environment for the arrival of the parasite, minutes
or hours after the initial bug bite. Recent results obtained
by our group demonstrated that injection of salivary LPC
into host skin followed by parasite inoculation in the same
site minutes later ultimately increases blood parasitemia
from 3- to 6-fold in animals infected with T. cruzi. LPC’s
eﬀect on parasitemia is mainly achieved by the activation
of macrophage chemotaxis and immunosuppression of NO
production induced by the parasite. We also showed an in-
crease in the rate of association of the parasite with macro-
phages induced either by 500-fold diluted saliva or by LPC.
This was the ﬁrst demonstration of a potentiating factor of
transmission of Chagas disease and the ﬁrst implication of a
lysophospholipid in an infectious disease [39].
The activation of receptors that recognize the parasite by
the presence of speciﬁc structures on its surface stimulates
host cells to produce TNF-α, IL-12, and NO, as mentioned
above. Depending on the MyD88 adapter protein, TLRs
2, 4, and 9 have been implicated in the network used
by the immune system of the mammalian host to control
infection by T. cruzi [14–18]. Campos et al. [18, 23]w e r e
the ﬁrst to demonstrate the involvement of TLR2 in the
interaction between the parasite and host macrophages. The
expression of TLR2 is essential for the induction of IL-12,
TNF-α, and NO, and this receptor is activated by parasite-
derived molecules such as GPI anchors, which have been
isolated from the surface of trypomastigotes of T. cruzi
[14–18]. The production of NO but not IL-12 by T. cruzi-
exposed macrophages is not aﬀected by bug saliva [39].
Curiously, in bone-marrow-derived macrophages obtained
from TLR2-deﬁcient mice, the production of IL-12 is largely
suppressed by LPC. These data indicate that in some cell
types, the production of this cytokine may be aﬀected by this
lysophospholipid through a TLR2-independent mechanism.
Moreover, GIPLs from T. cruzi are TLR4 agonists with
proinﬂammatory eﬀects [25, 26]. We showed that NO
production, induced by the parasite or by lipopolysaccharide
(LPS), another ligand of TLR4, either in murine peritoneal4 Journal of Parasitology Research
macrophages or bone marrow-derived macrophages, is
b l o c k e di nb o t hc a s e sb yL P Ce v e ni nt h ep r e s e n c eo f
IFN-γ in vitro [39]. The ability of LPC to reverse the induc-
tion of NO production in all cases, almost independently of
the ligand type, suggests that this lysophospholipid must act
by a unique pathway. In this regard, the receptors involved in
cell signaling induced by LPC, in general, exhibit a certain
promiscuity with respect to the ligand and vice versa. In
the case of LPC, diﬀerent receptors have been proposed for
this molecule, including G2A, a G protein-coupled receptor,
andGPR4,anotherimportantcandidate[45,47–49].Despite
the controversy generated in the literature due to the low
reproducibility of the studies using radioactive LPC and
its interaction with candidate receptors, the ability of G2A
to bind fatty acids and protons is noteworthy [33]. Thus,
G2A remains in the literature as the best-known receptor
involved in the adaptation of the signal induced by LPC [47–
49]. Moreover, the redistribution of G2A receptor itself and
the exposure of TLR4 are inﬂuenced by LPC metabolism
[33, 50]. In this case, the content of intracellular LPC is
ﬁnely controlled by the activity of a lysophosphatidylcholine
acyltransferase (LPCAT), an enzyme that uses LPC as a
substrate and generates phospholipids as the product of its
action. The treatment of monocytes with LPS activates this
enzyme and increases the transport of TLR4 to membrane
rafts in these cells [50]. Since the LPCAT inhibitor used,
5-hydroxyethyl 5 3  thiophenol pyridine (HETP), increases
the lysophospholipids/phospholipids ratios, it reverses the
eﬀect of LPS [50]. Thus, it seems appropriate to propose
that in the presence of T. cruzi, one should conduct a map
of the distribution of both receptors, G2A and TLR4, in the
presence and in the absence of LPC using both proteomic
and immunological methods [33, 50].
During programmed cell death, LPC is generated by
a calcium-independent PLA2 activated by caspase-3. Thus,
LPC acts as a chemotactic ﬁnd-me signal that attracts the
phagocyte to the apoptotic cells [49, 51, 52] and as an eat-
me signal involving recruitment of complement proteins for
recognition by phagocytes [49, 51, 52]. Such LPC-induced
chemotaxis is very interesting, because in Chagas disease,
the uptake of apoptotic cells by macrophages infected with
T. cruzi stimulates parasite growth [53]. In addition, it has
been shown that T. cruzi infective stages are able to generate
lipid messengers, including LPC, that modulate host cell
signaling [54]. Regarding adaptor molecules mobilized in
response to LPC, it is known that in most cell types, there
is the involvement of isoforms of protein kinase C [55].
Probably it is the type of isoform activated in each cell that
directs the intensity and type of response triggered by LPC
in that speciﬁc cell type. When combined with diﬀerent
types of TLRs and adapters, LPC-mediated signaling must
produce a speciﬁc and still poorly understood repertoire of
immunosuppression.
3. VectorPhospholipasesandEventualTargetto
Block T. cruzi Transmission
PLA2 is an enzyme family present in various organisms
such as viruses, bacteria, plants, and animals. According to
studies done on mammals, the action of PLA2 is important
for the remodeling of cell membranes, lipid digestion, cell
signaling, and immune defense of the host as well as
production of various lipid mediators [56–61]. In insects,
the phospholipases that have been studied are related to the
venom injected into their prey, the physiology of digestion,
immunity, and reproduction [61]. Among the published
studies on phospholipase activity in arthropods are those
reporting the presence of such enzymes in the salivary glands
of Manduca sexta [62] and in the saliva and salivary glands of
Amblyoma americanum [63, 64]. These studies have found a
correlation between PLA2 activity and digestion. In addition,
Zhu et al. [64] suggested another role for this activity,
linking it to the production of prostaglandins, promotion
of vasodilation and the suppression of inﬂammation and
immunity. The production of prostacyclin may also lead to
the inhibition of platelet aggregation and the induction of
vasodilation. Furthermore, platelet-activating factor (PAF)
acetyl hydrolase, a member of the GVII family of PLA2
enzymes, is a serine-dependent hydrolase that does not
require Ca2+ for activity. This enzyme cleaves the acetyl
group from the sn-2 position of the phospholipid, and in the
case of PAF, there is the hydrolysis of the sn-2 ester bond,
releasing acetate and biologically inactive lyso-PAF [65, 66].
Catﬂea(Ctenocephalidesfelis)salivaryglandhomogenatehas
a PAF-acetylhydrolase activity, and the estimated amount of
activity in a single pair of salivary glands (∼5pmol/min) is
of the right order of magnitude to induce a localized anti-
inﬂammatory/allergic eﬀect [67]. Extracellular PAF is proin-
ﬂammatoryandactsviaveryhighaﬃnity G-coupled protein
receptors, causing activation of platelets, neutrophils, and
monocytes [66]. The hypothesis is that PAF-acetylhydrolase
activities from saliva can downregulate inﬂammatory and
immune reactions mediated by PAF released from host cells.
This may happen as a reaction to injected cat ﬂea saliva
and may be interrupted by host grooming or scratching the
locale of the bite. Besides these reports, phospholipases also
have been identiﬁed in transcriptomes of saliva or salivary
glands of some hematophagous arthropods such as the soft
ticks Ornithodoros coriaceus [67, 68]a n dO. parkeri [69], of
hard ticks such as Ixodes paciﬁcus [70], and in insects such
as Anopheles funestus [71], Phlebotomus arabicus [72], and
Glossina morsitans [73].
Zeidner et al. [74] have suggested that aside from facili-
tating some tick digestive processes, it is possible that secre-
tion of PLA2 into the feed site creates some protective barrier
against bacteria that can be carried into the wound. They
demonstrated that the borreliacidal activity found in A.
americanum saliva is most probably due to the enzymatic
eﬀectsofPLA2 andthatitwoulddirectlyandrapidlykillBor-
relia burgdorgeri through the digestion of membrane lipids,
composed by a majority of PC and phosphatidylglycerol.
The authors hypothesize that high level of PLA2 enzymatic
a c t i v i t yp r e s e n ti ns a l i v ai sr e l a t e dt oA. americanum’s refrac-
toriness to B. burgdorgeri. Other studies have demonstrated
the importance of PLA2 in the infection processas elicited
by pathogens such as Toxoplasma gondii, Cryptosporium
parvum, Entamoeba histolytica, Leishmania amazonensis,a n d
T.cruzi[75–77]. Moreover, Connelly and Kierszenbaum [44]Journal of Parasitology Research 5
showed that the presence of PLA2 signiﬁcantly increased
the association between T. cruzi and macrophages, and they
suggest that this eﬀect relies on alterations of the parasite
membrane, since it was induced by pretreatment of parasite
membranes with PLA2 but not macrophages. But nowadays,
as cited above, the presence of PLA2 in salivary secretions
of T. cruzi vectors implies LPC generation and its further
involvement in the inﬂammatory process that occurs during
infection.
PLA2 enzymes from snake venom induce a wide spec-
trum of pharmacological eﬀects, including anticoagulant
proprieties that can be mediated by hydrolysis of phos-
pholipid or by a nonenzymatic mechanism, such as when
PLA2 from Naja nigricollis venom binds factor Xa in the
coagulation cascade through the speciﬁc anticoagulant site
on its surface [78]. Our group is investigating a further
role for the LPC present in the saliva of vectors, which we
believeisrelatedtomuscularparalysis.Rigonietal.[79]ha v e
shown that lysophospholipids, in particular LPC, can block
the exocytosis of neurotransmitters, thus paralyzing the
muscle. In this context, using the predator insect Belostoma
anurum as model, we showed that the salivary LPC also
has this property. Our hypothesis is that B. anurum uses
lysophospholipids as a way to paralyze the prey while it
feeds, since it makes anextraoral digestion [80]. We obtained
similar results with LPC from R. prolixus,w i t hl e s sp r o -
nounced blockage of exocytosis. LPC action may be more
local in order to avoid disturbing the host. Thus, the above
data show that the presence of LPC generated by PLA2si n
salivarysecretionsofpredatorsandblood-suckingarthopods
is widespread in the animal kingdom, and this molecule may
be a surviving trace of ancient feeding habits.
Another aspect that should be emphasized is that PLA2s
alsogeneratefreefattyacidsthatcanbeconvertedtoeicosan-
oids. Eicosanoids are polyunsaturated fatty acids of 20 car-
bons that act as local mediators of short half-life; they are
derived from arachidonic acid (20:4 n-6) or other polyun-
saturated 20-carbon precursors (20:3 n-6 and 20:5 n-3).
Arachidonic acid is esteriﬁed in phospholipids of plasma
membranes, these being released by the action of PLA2.T h e
biological action of arachidonic acid products requires its
oxygenation, which can take place in three diﬀerent ways:
(a) via the cyclooxygenases that generate prostaglandins
and thromboxanes, (b) via the lipooxygenases that generate
leukotrienes and lipoxins, and (c) via the cytochrome P-
450, which generates epoxides [81]. Physiological processes
that usually involve autacoids, hormones, and growth factors
may stimulate the release of arachidonic acid, as already
widely described in mammals, as in mediating immune and
inﬂammatory response of late vertebrates [82]. Recently, the
involvement of thromboxane A2 (TXA2) in the process of
vertebrate host infection by T. cruzi [83] was demonstrated.
The same group showed that the eicosanoid TXA2 is preva-
lent in all life stages of the parasite. Thus, in infected mice,
the parasite itself may account for 90% of the total TXA2 in
plasma. In this regard, it is noteworthy that the production
of TXA2 from arachidonic acid occurs by the cyclooxygenase
pathway. Accordingly, results from our laboratory indicate
that half of the fatty acids ingested along with blood are
unsaturated and about half of them are arachidonic acid. So,
i fap o o lo fT X A 2 is a prerequisite for the process of infection
of host cells by any pathogen, that pool could be generated
during the ﬁnal stages of blood digestion in the vector at
the expense of fatty acids released there. A triacylglycerol-
lipase activity was identiﬁed in the gut lumen of blood-fed
insects and is probably involved in the digestion of lipids
from the blood meal. These lipase activities and also the
metabolism and fate of lipids that are generated during
digestion of ingested blood were studied and characterized
[84]. However, neither the dynamic generation of free fatty
acids in insects infected with T. cruzi nor their processing
to TXA2 in the ﬁnal stage of the digestive process has ever
been assessed in any vector. Thus, an attractive model for the
futuremightinvolvethesilencingofaPLA2 geneinthesaliva
ofChagasdiseasevectorstoobtainLPC-depletedorLPC-free
saliva. The saliva of these insects would be expected to lower
the rate of infection of the vertebrate host.
4. The Role of Host PlasmaLPC in
T. cruzi Infection
The original studies that implicated LPC in the pathogenesis
of atherosclerosis tended to highlight the presence of this
phospholipid in atheromatous lesions [37]. However, the
origin and dynamics of the formation of this molecule
remained unknown for many years. Wilensky et al. [85]
identiﬁed the main enzyme responsible for the generation of
LPC, Lp-PLA2, also known as PAF-acetyl hydrolase or phos-
pholipase VIIA, which is secreted by leukocytes and associ-
ated with plasma lipoproteins, especially LDL. This enzyme
recognizes and cleaves oxLDL and oxidized phospholipids,
generating LPC and free fatty acid oxidation (oxNEFAS, or
oxidized nonesteriﬁed fatty acids). The LPC, as previously
mentioned, is a potent proinﬂammatory molecule capable
of leukocyte recruitment and activation with induction of
apoptosis. Demonstration of Lp-PLA2 in the necrotic core of
atheromatous lesions and ﬁbrous cap of vulnerable plaques
supports our current views of the importance of this enzyme
in atherogenesis. An important therapeutic option is the
selective inhibition of Lp-PLA2. Wilensky et al. [85] showed
that the administration of darapladib (GlaxoSmithKline) in
experimental models selectively reduces the activity of this
enzyme, attenuates the formation of LPC, and reduces the
formationofatheroscleroticplaqueswithnegativeregulation
of proinﬂammatory genes in macrophages and T lympho-
cytes. Chagas disease treatment aims to slow the progression
of myocardial impairment caused by invasion of the patient’s
heart by the parasite. Some of the drugs used to treat Chagas
disease cause changes in the patients plasma lipid proﬁle,
leading to high concentrations of LDL. During treatment,
these patients are likely to present favorable conditions
for LDL oxidation and generation of LPC, which will
certainly trigger the proinﬂammatory phenotype, thereby
maintaining levels of reinfection of myocardial cells. In this
sense, it would be important to evaluate the generation
of LPC in Chagas disease patients treated with various
categories of drugs in order to verify the formation of this
lipid mediator. Likewise, chronic treatment with the drug6 Journal of Parasitology Research
in healthy experimental animals should be carried out to
identify any eﬀects on the levels of LPC and subsequent sus-
ceptibility to infection by T. cruzi. In conclusion, darapladib
may constitute a novel tool with dual use: to optimize the
current therapeutic treatment of chronic chagasic patients
and to experimentally modify the plasma levels of LPC in
mice to determine whether the reduction of such levels
decreases the susceptibly to infection by T. cruzi.
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